Drug
Sparsentan clinical trials
Also written RE-021 and PS433540.
Keep track of what changes. Save the sparsentan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2014 | 1 |
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 3
Travere Therapeutics, Inc. (7) · Ligand Pharmaceuticals (2) · University of Edinburgh (1) · Brigham and Women's Hospital (1) · University of Leicester (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses sparsentan is read from its arms, and is right about nine times in ten.
Testing it · 12
- Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated ProteinuriaRecruitingPhase 1Brigham and Women's HospitalNCT07224776Written as sparsentan
- A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A NephropathyRecruitingPhase 2University of LeicesterNCT04663204Written as Sparsentan
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesRecruitingPhase 2Travere Therapeutics, Inc.NCT05003986Written as Sparsentan
- A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyCompletedPhase 3Travere Therapeutics, Inc.NCT03762850Written as sparsentan
- ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)Active, not recruitingPhase 2University of EdinburghNCT05630612Written as Sparsentan
- Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental GlomerulosclerosisActive, not recruitingPhase 4Travere Therapeutics, Inc.NCT07219121Written as Sparsentan
- Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)CompletedPhase 3Travere Therapeutics, Inc.NCT03493685Written as sparsentan
- A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgANCompletedPhase 2Travere Therapeutics, Inc.NCT05856760Written as Sparsentan
- Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisCompletedPhase 2Travere Therapeutics, Inc.NCT01613118Written as RE-021 (Sparsentan)
- Study to Evaluate the Pharmacokinetics of Oral Sparsentan SuspensionCompletedPhase 1Travere Therapeutics, Inc.NCT05562362Written as RE-021, sparsentan
- A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat HypertensionCompletedPhase 2Ligand PharmaceuticalsNCT00522925Written as PS433540
- A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With HypertensionCompletedPhase 2Ligand PharmaceuticalsNCT00635232Written as PS433540
Codes
What other systems call sparsentan · ClinicalTrials.gg INT001171
- MeSH (NLM) C000634424sparsentanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9242RO5URMSPARSENTANConfirmed FDA, NLM, Wikidata
- Wikidata Q27088845sparsentanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152412SparsentanOne source FDA
- DrugBank DB12548One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000634424 | sparsentan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9242RO5URM | SPARSENTAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088845 | sparsentan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152412 | Sparsentan | One source FDA |
| DrugBank | DB12548 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.